Brinker Capital Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Brinker Capital Investments’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,682	Closed	-$273K	–	1695
2023 Q2	$273K	Buy	2,682 +5	+0.2%	+$473	﹤0.01%	1438
2023 Q1	$243K	Buy	+2,677	New	+$157K	﹤0.01%	1423

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brinker Capital Investments's RETA Position: Q3 2023 in Review

Brinker Capital Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,682 shares — an estimated $273K sold.

Brinker Capital Investments first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $273K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Brinker Capital Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Brinker Capital Investments sold 2,682 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $273K.
Brinker Capital Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Brinker Capital Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $273K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Brinker Capital Investments's 13F filing for Q3 2023, filed 31 Jul 2025.